Información: Esta es una versión obsoleta del modelo de datos. En la sección izquierda, bajo "Versiones", se encuentra el historial de versiones. Puede acceder a la versión actual a través del siguiente link: here.
Información:
Error:
ID
27837
Descripción
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz
Palabras clave
Versiones (2)
- 30/11/17 30/11/17 -
- 4/1/18 4/1/18 -
Titular de derechos de autor
Prof. Dr. med. Georg Heß
Subido en
30 de noviembre de 2017
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Screening Exclusion criteria GOAL Trial B-cell Lymphoma NCT02499003
Screening Exclusion criteria GOAL Trial B-cell Lymphoma NCT02499003
Similar models
Screening Exclusion criteria GOAL Trial B-cell Lymphoma NCT02499003
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Subject ID
Item
Subject ID
text
Other lymphoma
Item
1. Lymphoma other than DLBCL, FL IIIB, transfomed indolent NHL
boolean
CNS involvement
Item
2. CNS involvement (brain MRI is required only in cases of clinically suspicious involvement)
boolean
Pregnancy
Item
3. Pregnant or breastfeeding women
boolean
Severe concomitant disease
Item
4. Severe concomitant disease
boolean
Myocardial infarction within the last 6 months
Item
5. Myocardial infarction within the last 6 months
boolean
Active uncontrolled infections
Item
6. Active uncontrolled infections incl. HIV-positivity, active Hepatitis B or C
boolean
Vaccination
Item
7. Vaccination with live vaccine within last 4 weeks
boolean
Mental status
Item
8. Mental status precluding patient's compliance
boolean
CD20 negativity
Item
9. Known CD20 negativity
boolean
malignancy other than NHL
Item
10. Diagnosed or treated for a malignancy other than NHL
boolean
Treatment with anticancer agent
Item
11. Treatment with any approved anticancer agent within last 2 weeks
boolean
exposition to Obinutuzumab or Pixantrone
Item
12. Prior exposition to Obinutuzumab or Pixantrone
boolean
hypersensitivity to medicinal products
Item
13. History of hypersensitivity to medicinal products with similar chemical structure as the trial medication
boolean
participation in other interventional clinical trials
Item
14. Active participation in other interventional clinical trials during the present clinical trial or within the last 2 weeks prior to treatment initiation
boolean
Medical or psychological conditions
Item
15. Medical or psychological conditions that would jeopardize an adequate and orderly completion of the trial.
boolean
Sin comentarios